PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called “KGF alternative- peptide (FGFR2b agonist)” which is functionally equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
New York Blood Center Enterprises and Human Life CORD Sign Letter of Intent to Expand Manufacturing Collaboration for Umbilical Cord -Derived MSCs
Summary: New York Blood Center Enterprises (NYBCe) and Human Life CORD Japan Inc. have signed a Letter of Intent to expand their partnership in manufacturing mesenchymal stromal cells (MSCs) through NYBCe’s Comprehensive Cell Solutions (CCS). This collaboration aims to standardize and scale the production of umbilical cord-derived MSCs, enhancing global supply chain reliability and advancing regenerative medicine. By combining U.S. and Japanese capabilities, the partnership seeks to accelerate clinical and commercial development, making advanced cell therapies more accessible worldwide.
Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies
New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases
CAMBRIDGE, Mass., March 04, 2025 — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company. [Read more…]
Coeptis Therapeutics to Pursue Phase 2 Program Using Allogeneic Cord-Blood Derived NK Cell Therapy
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death
DVX201 is the world’s first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ hematopoietic stem and progenitor cells (HSPC) cells.
WEXFORD, PA, Feb 7, 2024 — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the “tripledemic” of influenza, COVID-19 and respiratory syncytial virus (RSV). [Read more…]
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
CHICAGO, IL, January 11, 2025 — VectorBuilder’s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 62
- Next Page »